Biomaterials Translational ›› 2022, Vol. 3 ›› Issue (2): 152-161.doi: 10.12336/biomatertransl.2022.02.007

• RESEARCH ARTICLE • Previous Articles     Next Articles

Graphene-incorporated hyaluronic acid-based hydrogel as a controlled Senexin A delivery system

Panita Maturavongsadit1, Weiwei Wu2, Jingyu Fan1, Igor B. Roninson3, Taixing Cui2,*(), Qian Wang1,*()   

  1. 1 Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA
    2 Department of Cell Biology and Anatomy School of Medicine Columbia, University of South Carolina, Columbia, SC, USA
    3 Department of Drug Discovery & Biomedical Sciences, College of Pharmacy, University of South Carolina, Columbia, SC, USA
  • Received:2022-04-11 Revised:2022-05-16 Accepted:2022-05-30 Online:2022-06-28 Published:2022-06-28
  • Contact: Taixing Cui,Qian Wang E-mail:Taixing.Cui@uscmed.sc.edu;wang263@mailbox.sc.edu
  • About author:Qian Wang, wang263@mailbox.sc.edu.
    Taixing Cui, Taixing.Cui@uscmed.sc.edu;


Perivascular delivery of therapeutic agents against established aetiologies for occlusive vascular remodelling has great therapeutic potential for vein graft failure. However, none of the perivascular drug delivery systems tested experimentally have been translated into clinical practice. In this study, we established a novel strategy to locally and sustainably deliver the cyclin-dependent kinase 8/19 inhibitor Senexin A (SenA), an emerging drug candidate to treat occlusive vascular disease, using graphene oxide-hybridised hyaluronic acid-based hydrogels. We demonstrated an approach to accommodate SenA in hyaluronic acid-based hydrogels through utilising graphene oxide nanosheets allowing for non-covalent interaction with SenA. The resulting hydrogels produced sustained delivery of SenA over 21 days with tunable release kinetics. In vitro assays also demonstrated that the hydrogels were biocompatible. This novel graphene oxide-incorporated hyaluronic acid hydrogel offers an optimistic outlook as a perivascular drug delivery system for treating occlusive vascular diseases, such as vein graft failure.

Key words: controlled drug delivery, graphene oxide, hyaluronic acid-based hydrogel, Senexin A